ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SIGA / forecast
NATR (64) ELDN (37) KROS (64) ACIU (45) ⌘ Pro Terminal →

SIGA Technologies Inc. (SIGA) 12-Month Stock Forecast & Price Target Cone

$2.95 -2.96% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.93

SIGA Technologies Inc. (SIGA) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $212.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SIGA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SIGA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, SIGA Technologies Inc. (NASDAQ: SIGA) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $2.95 (-2.96% 1D, market cap $212.0M). Pillar breakdown: Fundamental Cash Engine 20/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, SIGA ranks #96 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SIGA compare to NATR and ELDN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SIGA carries a Roarable C+ (68/100 RQD), trailing P/E of 9.8x, gross margin of 68.6%, and ROIC of 42.7%. By comparison, NATR (Nature's Sunshine Products Inc.) holds a C grade (64/100 RQD, P/E 11.1x, ROIC 28.9%, cap $211.5M) and ELDN (Eledon Pharmaceuticals Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $212.9M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SIGA?
▼

Per SIGA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001010086), SIGA Technologies Inc. generated $94.6M in revenue (-31.8% YoY), $23.3M in net income, and $43.5M in free cash flow against $219.5M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (68.6% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.93 (-0.72%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 20/20 (A+) • 46% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY • 56.9% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510068
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C+ · Rk C+
Cash (20)Whales (4)SEC (16)Macro (11)CEO (17)
Each axis scored 0–20
12M PRICE TARGET CONE+4.4% Base Target
$9 Bull$3 Base$2 Bear
📬 FREE SIGA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SIGA)Realized 20D OHLCV Swing Band: ±8.4%
Deterministic 5-Pillar Attribution (68/100 Composite)
🔍 WHY SIGA SCORES 68/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+20/20 pts (29% of score)

SEC XBRL FY 2025 (10-K): 46% FCF Margin ($43.5M FCF) & 68.6% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (25% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
76
Grade B+$3.10+0.6% Next Q
Q2 (-2Q)
73
Grade B$3.12+6.1% Next Q
Q3 (-1Q)
71
Grade B$3.31-10.9% Next Q
Current
68
Grade C+$2.95+1.8% Hist 90D α
Trajectory: B+ (76) → C+ (68)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the SIGA Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 68/100 (C+) score, SIGA faces multiple-compression risk if 9.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 66.1% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.18) or 200D SMA ($4.33) invalidates the momentum regime and cuts Target Base ($3.08) toward Bear Floor ($2.40).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SIGA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SIGA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 68%NO 32%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your SIGA Position Size: $10,000

Shares at $2.95: 3389.8 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $2.40
$8,136
$-1,864 (-18.6%)
12M Consensus BaseTarget $3.08
$10,441
+$441 (+4.4%)
12M Bull Case BreakoutTarget $8.88
$30,102
+$20,102 (+201.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$374%A
Goldman SachsSector Coverage LeadBUY$869%B
JP MorganUS Large-Cap ResearchHOLD$358%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (SIGA Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SIGA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -36.42%🛡️ HOLDING TREND SUPPORT
2026-11-04O $3.04H $3.04L $2.95C $2.95VOL 701.3K
RES: $3.41SUP: $2.91SMA50: $3.18SMA200: $4.33
$7.14$5.97$4.80$3.64$2.47RES $3.41SUP $2.91$2.952026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SIGA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SIGA Butterfly Map → + Track SIGA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-1.6%/yr Implied 5Y Growth

vs. -31.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SIGA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SIGA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SIGA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SIGA)

Health Care Rank #96 of 1015 ⚔️ NATR vs SIGA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SIGA vs. NATR, ELDN, KROS, ACIU)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, SIGA Technologies Inc. (SIGA) ranks #96 by composite RQD confidence (68/100, grade C+) and #562 by equity capitalization ($212.0M). Within this direct 5-issuer industry benchmark cohort, SIGA leads on earnings valuation at 9.8x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. SIGA currently leads its immediate peer cohort in composite quantitative strength at 68/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SIGA ACTIVE
SIGA Technologies Inc.
C+ 68/100 9.8x 68.6% 42.7% -2.96% $212.0M Benchmark Subject
NATR
Nature's Sunshine Products Inc.
C 64/100 11.1x 72.4% 28.9% -1.88% $211.5M /natr-vs-siga →
ELDN
Eledon Pharmaceuticals Inc.
D- 37/100 — — -35.0% -5.41% $212.9M /eldn-vs-siga →
KROS
Keros Therapeutics Inc.
C 64/100 — — 85.0% -2.54% $213.3M /kros-vs-siga →
ACIU
AC Immune SA
D 45/100 — — — -7.21% $209.7M /aciu-vs-siga →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001010086 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SIGA Technologies Inc. (SIGA) reported GAAP revenue of $94.6M (-31.8% vs. FY2024 revenue of $138.7M , and -32.4% cumulative change since FY2023) , GAAP net income of $23.3M, operating cash flow of $43.5M, and free cash flow of $43.5M (-10.8% YoY). On the balance sheet, SIGA closed FY2025 with $219.5M in total assets against $0 in total debt (Altman Z-Score: 8.22, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $94.6M $23.3M $43.5M $43.5M $219.5M —
FY2024 (FY) 2024-12-31 $138.7M $59.2M $48.8M $48.8M $244.3M —
FY2023 (FY) 2023-12-31 $139.9M $68.1M $94.8M $94.8M — —

3. SIGA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SIGA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, SIGA Technologies Inc. (NASDAQ: SIGA) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $2.95 (-2.96% 1D, market cap $212.0M). Pillar breakdown: Fundamental Cash Engine 20/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, SIGA ranks #96 in composite RQD confidence.

How does SIGA compare to NATR and ELDN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SIGA carries a Roarable C+ (68/100 RQD), trailing P/E of 9.8x, gross margin of 68.6%, and ROIC of 42.7%. By comparison, NATR (Nature's Sunshine Products Inc.) holds a C grade (64/100 RQD, P/E 11.1x, ROIC 28.9%, cap $211.5M) and ELDN (Eledon Pharmaceuticals Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $212.9M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SIGA?

Per SIGA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001010086), SIGA Technologies Inc. generated $94.6M in revenue (-31.8% YoY), $23.3M in net income, and $43.5M in free cash flow against $219.5M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (68.6% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SIGA trading relative to its 50-day, 200-day, and 52-week technical levels?

SIGA last traded at $2.95 (-2.96% on volume of 701,296 shares), positioning the stock -7.23% below its 50-day simple moving average ($3.18) and -31.87% below its 200-day simple moving average ($4.33). Across its 52-week range of $2.83 to $8.46, SIGA sits at the 2.1% percentile with a 14-day RSI of 39.8 (NEUTRAL RANGE) and an implied next-earnings move of ±8.4% ($2.70 to $3.20).

Direct Sub-Reports: SIGA RQD Cockpit SIGA 12M Forecast SIGA Earnings & Move SIGA Dividends & DRIP SIGA Insiders & 13F SIGA Whale Options SIGA Profit Sankey SIGA News & Why
ROARABLE RATING BRIEF • RQD 68/100 (C+) ✓ SEC XBRL & RQD VERIFIED

SIGA — SIGA Technologies Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

SIGA Technologies Inc. (SIGA) earns a live Roarable RQD composite score of 68/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $2.95 (-2.96% 1D, market capitalization $212.0M).

  • Fundamental Cash Engine (20/20): Anchored by return on invested capital (ROIC) of 42.7%, gross margin of 68.6%, operating margin of 25.1%, and free cash flow yield of 19.03%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (17/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 8.22, Piotroski F-Score of 6/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

SIGA Technologies Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. Per the recent news wire, the company has a contract with Public Services and Procurement Canada to supply Oral TPOXX to the Canadian Department of National Defence.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), SIGA Technologies Inc. (SIGA) reported $94.6M in annual revenue (up from $138.7M in FY2024, -31.8% YoY) and $23.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($139.9M revenue, $68.1M net income) through FY2025, SIGA scaled operating cash flow to $43.5M and free cash flow to $43.5M, backed by $219.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C+ • RQD 68/100): Strong cash generator (68.6% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 20/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $2.83 – $8.46 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 9.8x trailing P/E and 4.8x EV/EBITDA against 25.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

For a prospective investor, the lack of mapped upstream suppliers, downstream customers, or sector correlations means second-order ripples cannot be assessed from the data provided. The one identified customer relationship (Canadian government defense procurement, per the news wire) is a single-counterparty dependency that a careful investor would want to examine further, since revenue concentration risk cannot be measured with the current source data.

  • Key Question #1: Can SIGA sustain or expand its 25.1% operating margin and 42.7% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $94.6M and free cash flow of $43.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SIGA's 9.1x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SIGA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SIGA Technologies Inc. (SIGA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SIGA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SIGA Bull vs. Bear Conversation Board — What's Your Call at $2.95?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SIGA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SIGA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $3.83 (+26.0%)
📌 Pinned Debate

A 42.7% ROIC and 19.03% FCF yield at a 9.8 P/E TTM show a cash engine priced at a low multiple.

Long SIGA at $3.04 targeting $3.83. A 42.7% ROIC and 19.03% FCF yield at a 9.8 P/E TTM show a cash engine priced at a low multiple.. Institutional whale score is 4/20 and the risk/reward vs. the $2.83 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@ForensicBear Fair point on 9.8x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (68.6%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $2.46 (-19.1%)
Spot @ $3.04

Revenue fell from $138.7M in FY 2024 to $94.6M in FY 2025 while operating income dropped from $83.6M to $23.7M over two years.

Sitting on the sidelines or leaning short SIGA above $3.04. Revenue fell from $138.7M in FY 2024 to $94.6M in FY 2025 while operating income dropped from $83.6M to $23.7M over two years.. Until Fundamental Cash Engine (20/20) and FCF yield (19.03%) inflect higher, upside is capped near $8.46.

LIVE TAPE